Review: Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control
Free accessReview articleFirst published online October, 2010
Review: Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control
European guidelines recommend that treating patients with hypertension to blood pressure (BP) goal is an important target for cardiovascular (CV) risk reduction. However, office BP may be a suboptimal target, given its limitations. Indeed, there is evidence that 24-h ambulatory BP monitoring (ABPM) parameters may score better in this regard, representing more accurate predictors of CV risk. In particular, mean 24-h BP and BP variability both correlate closely with hypertension end-organ damage and rate of CV events, which suggests that antihypertensive therapy should provide smooth BP control over the full 24-h dosing interval. The use of ABPM has demonstrated that fixed-dose combination therapy, comprising agents with complementary mechanisms of action, may overcome the challenge of suboptimal BP control by providing improvements in antihypertensive efficacy and tolerability throughout the 24-h period. Olmesartan/amlodipine is one of the latest combination therapies to be approved, and a number of large clinical trials have demonstrated the efficacy and tolerability of this combination in patients with mild-to-severe hypertension. Furthermore, recent ABPM studies of olmesartan/amlodipine-based treatment algorithms have shown the satisfactory 24-h antihypertensive efficacy of this fixed-dose combination. This review provides an overview of recent clinical data on the efficacy and tolerability of fixed-dose olmesartan/amlodipine combination therapy for the treatment of mild-to-severe hypertension, with a focus on sustained 24-h BP control.
Bakris, G.L. ( 2008) Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 10(1 Suppl 1): 27-32.
2.
Barrios, V., Brommer, P., Haag, U., Calderon, A. and Escobar, C.(2009) Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: A randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig29: 427-439.
3.
Benetos, A., Thomas, F., Bean, K.E. and Guize, L. ( 2003) Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens21: 1635-1640.
4.
Bilo, G., Giglio, A., Styczkiewicz, K., Caldara, G., Maronati, A., Kawecka-Jaszcz, K. et al. (2007) A new method for assessing 24-h blood pressure variability after excluding the contribution of nocturnal blood pressure fall . J Hypertens25: 2058-2066.
5.
Bjorklund, K., Lind, L., Zethelius, B., Berglund, L. and Lithell, H. ( 2004) Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men . J Hypertens22: 1691-1697.
6.
Chrysant, S., Melino, M., Karki, S., Lee, J. and Heyrman, R. ( 2008) The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther30: 587-604.
7.
Chrysant, S.G., Oparil, S., Melino, M., Karki, S., Lee, J. and Heyrman, R.(2009) Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension . J Clin Hypertens (Greenwich) 11: 475-482.
8.
Coca, A., Picado, M.J., De la Sierra, A., Aguilera, M.T., Sanchez, M., Lluch, M.M. et al. (1993) Comparative evaluation of the antihypertensive efficacy of once-daily amlodipine versus nitrendipine with 24-hour ambulatory blood pressure monitoring in essential hypertension. J Cardiovasc Pharmacol22: 513-518.
9.
Delgado-Mederos, R., Ribo, M., Rovira, A., Rubiera, M., Munuera, J., Santamarina, E. et al. (2008) Prognostic significance of blood pressure variability after thrombolysis in acute stroke. Neurology71: 552-558.
10.
Dolan, E., Stanton, A., Thijs, L., Hinedi, K., Atkins, N., McClory, S. et al. (2005) Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: The Dublin outcome study. Hypertension46: 156-161.
11.
Eguchi, K., Ishikawa, J., Hoshide, S., Pickering, T.G., Schwartz, J.E., Shimada, K. et al. (2009) Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens22: 46-51.
12.
Eto, M., Toba, K., Akishita, M., Kozaki, K., Watanabe, T., Kim, S. et al. (2005) Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens Res28: 1-7.
13.
Ezzati, M., Lopez, A.D., Rodgers, A., Vander Hoorn, S. and Murray, C.J. ( 2002) Selected major risk factors and global and regional burden of disease. Lancet360: 1347-1360.
14.
Fabia, M.J., Abdilla, N., Oltra, R., Fernandez, C. and Redon, J. ( 2007) Antihypertensive activity of angiotensin II AT1 receptor antagonists: A systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens25: 1327-1336.
15.
Frattola, A., Parati, G., Cuspidi, C., Albini, F. and Mancia, G. ( 1993) Prognostic value of 24-hour blood pressure variability . J Hypertens11: 1133-1137.
16.
Giles, T.D. ( 2006) Circadian rhythm of blood pressure and the relation to cardiovascular events. J Hypertens24(Suppl): S11-S16.
17.
Gosse, P., Lasserre, R., Minifie, C., Lemetayer, P. and Clementy, J. ( 2004) Blood pressure surge on rising. J Hypertens22: 1113-1118.
18.
Hasler, C., Nussberger, J., Maillard, M., Forclaz, A., Brunner, H.R. and Burnier, M. ( 2005) Sustained 24-hour blockade of the renin-angiotensin system: A high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther78: 501-507.
19.
Heagerty, A.M., Laeis, P. and Haag, U. ( 2009) Olmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy - additional effect by uptitration in patients with moderate-to-severe hypertension. J Hypertens27(Suppl 4): S283.
20.
Jamerson, K., Weber, M.A., Bakris, G.L., Dahlof, B., Pitt, B., Shi, V. et al. (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med359: 2417-2428.
21.
Jamerson, K.A., Nwose, O., Jean-Louis, L., Schofield, L., Purkayastha, D. and Baron, M. ( 2004) Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens17: 495-501.
22.
Jinno, T., Iwai, M., Li, Z., Li, J.M., Liu, H.W., Cui, T.X. et al. (2004) Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension43: 263-269.
23.
Kario, K., Pickering, T.G., Umeda, Y., Hoshide, S., Hoshide, Y., Morinari, M. et al. (2003) Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study. Circulation107: 1401-1406.
24.
Kikuya, M., Hozawa, A., Ohokubo, T., Tsuji, I., Michimata, M., Matsubara, M. et al. (2000) Prognostic significance of blood pressure and heart rate variabilities: The Ohasama study. Hypertension36: 901-906.
25.
Kikuya, M., Ohkubo, T., Metoki, H., Asayama, K., Hara, A., Obara, T. et al. (2008) Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: The Ohasama study. Hypertension52: 1045-1050.
26.
Lawes, C.M., Vander Hoorn, S. and Rodgers, A. ( 2008) Global burden of blood-pressure-related disease, 2001 . Lancet371: 1513-1518.
27.
Mancia, G., Bertinieri, G., Grassi, G., Parati, G., Pomidossi, G., Ferrari, A. et al. (1983) Effects of blood-pressure measurement by the doctor on patient’s blood pressure and heart rate. Lancet2: 695-698.
28.
Mancia, G., Bombelli, M., Facchetti, R., Madotto, F., Corrao, G., Trevano, F.Q. et al. (2007a) Long-term prognostic value of blood pressure variability in the general population: Results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension49: 1265-1270.
29.
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G. et al. (2007b) 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J28: 1462-1536.
30.
Mancia, G., Di Rienzo, M. and Parati, G. ( 1993) Ambulatory blood pressure monitoring use in hypertension research and clinical practice. Hypertension21: 510-524.
31.
Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M.J. et al. (2009) Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens27: 2121-2158.
32.
Mena, L., Pintos, S., Queipo, N.V., Aizpurua, J.A., Maestre, G. and Sulbaran, T. ( 2005) A reliable index for the prognostic significance of blood pressure variability. J Hypertens23: 505-511.
33.
Neutel, J.M., Kereiakes, D.J., Punzi, H., Shojaee, A., Waverczak, W.F., Dubiel, R. et al. (2009a) Efficacy and safety of an amlodipine (AML)/olmesartan medoxomil (OLM)-based titration regimen on blood pressure (BP) assessed by mean 24 hr ambulatory BP monitoring (ABPM) in patients with hypertension. J Clin Hypertens (Greenwich) 11: A129-A130.
34.
Neutel, J.M., Littlejohn III, T., Shojaee, A., Waverczak, W.F., Dubiel, R. and Xu, J. ( 2009b) 24 hour efficacy of an amlodipine (AML)/olmesartan medoxomil (OM)-based titration regimen on blood pressure (BP) at daytime, nighttime and last 6, 4, 2 hours of dosing interval. J Clin Hypertens (Greenwich) 11: A130.
35.
Oparil, S., Lee, J., Karki, S. and Melino, M.(2009) Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: Evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol54: 427-436.
36.
Palatini, P. ( 2005) Combination therapy in the management of hypertension: Focus on angiotensin receptor blockers combined with diuretics. J Clin Hypertens (Greenwich) 7: 96-101.
37.
Palatini, P., Dorigatti, F., Mugellini, A., Spagnuolo, V., Vari, N., Ferrara, R. et al. (2004) Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: Insights from the Val-Syst Study. Clin Ther26: 1436-1445.
38.
Palatini, P., Penzo, M., Racioppa, A., Zugno, E., Guzzardi, G., Anaclerio, M. et al. (1992) Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med152: 1855-1860.
39.
Parati, G. ( 2005) Blood pressure variability: Its measurement and significance in hypertension. J Hypertens23(Suppl): S19-S25.
40.
Parati, G. and Bilo, G. ( 2008) Clinical relevance of day-by-day blood pressure and heart rate variability: New information from home self-measurements. Hypertension52: 1006-1008.
41.
Parati, G. and Bilo, G. ( 2009) Olmesartan medoxomil/ amlodipine improves blood pressure control throughout 24 hours as compared to amlodipine monotherapy in patients with moderate-to-severe hypertension. Poster presented at: The 2nd International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes mellitus, Valencia.
42.
Parati, G., Omboni, S., Albini, F., Piantoni, L., Giuliano, A. and Revera, M.(2009a) Home blood pressure telemonitoring improves hypertension control in general practice. The TeleBPCare study. J Hypertens27: 198-203.
43.
Parati, G., Omboni, S. and Bilo, G.(2009b) Why is out-of-office blood pressure measurement needed? Home blood pressure measurements will increasingly replace ambulatory blood pressure monitoring in the diagnosis and management of hypertension. Hypertension54: 181-187.
44.
Parati, G., Omboni, S., Rizzoni, D., Agabiti-Rosei, E. and Mancia, G. ( 1998) The smoothness index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens16: 1685-1691.
45.
Parati, G. and Pickering, T.G.(2009) Home blood-pressure monitoring: US andEuropean consensus. Lancet373: 876-878.
46.
Parati, G., Pomidossi, G., Albini, F., Malaspina, D. and Mancia, G. ( 1987) Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens5: 93-98.
47.
Parati, G., Stergiou, G.S., Asmar, R., Bilo, G., de Leeuw, P., Imai, Y. et al. (2008) European Society of Hypertension guidelines for blood pressure monitoring at home: A summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens26: 1505-1526.
48.
Parati, G. and Valentini, M. ( 2006) Prognostic relevance of blood pressure variability. Hypertension47: 137-138.
49.
Parati, G. and Valentini, M. ( 2007) Do we need out-of-office blood pressure in every patient ? Curr Opin Cardiol22: 321-328.
50.
Pereira, M., Lunet, N., Azevedo, A. and Barros, H. ( 2009) Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens27, (online early section).
51.
Pickering, T.G. ( 2008) When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens2: 119-124.
52.
Pickering, T.G., Shimbo, D. and Haas, D. ( 2006) Ambulatory blood-pressure monitoring. N Engl J Med354: 2368-2374.
53.
Pierdomenico, S.D., Di Nicola, M., Esposito, A.L., Di Mascio, R., Ballone, E., Lapenna, D. et al. (2009) Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens22: 842-847.
54.
Pringle, E., Phillips, C., Thijs, L., Davidson, C., Staessen, J.A., de Leeuw, P.W. et al. (2003) Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population . J Hypertens21: 2251-2257.
55.
Rosenthal, T. and Gavras, I. ( 2006) Fixed-drug combinations as first-line treatment for hypertension . Prog Cardiovasc Dis48: 416-425.
56.
Rothwell, P.M., Howard, S.C., Dolan, E., O’Brien, E., Dobson, J.E., Dahlof, B. et al. (2010) Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet375: 895-905.
57.
Sander, D., Kukla, C., Klingelhofer, J., Winbeck, K. and Conrad, B. ( 2000) Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study . Circulation102: 1536-1541.
58.
Schillaci, G. and Parati, G.(2010) Determinants of blood pressure variability in youth: At the roots of hypertension. J Hypertens28: 660-664.
59.
Sega, R., Facchetti, R., Bombelli, M., Cesana, G., Corrao, G., Grassi, G. et al. (2005) Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation111: 1777-1783.
60.
Staessen, J.A., Thijs, L., Fagard, R., O’Brien, E.T., Clement, D., de Leeuw, P.W. et al. (1999) Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA282: 539-546.
61.
Stumpe, K.O. ( 2004) Olmesartan compared with other angiotensin II receptor antagonists: Head-to-head trials. Clin Ther26(Suppl A): A33-A37.
62.
Tatasciore, A., Renda, G., Zimarino, M., Soccio, M., Bilo, G., Parati, G. et al. (2007) Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension50: 325-332.
63.
Tozawa, M., Iseki, K., Yoshi, S. and Fukiyama, K. ( 1999) Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant14: 1976-1981.
64.
Verdecchia, P., Angeli, F., Gattobigio, R., Rapicetta, C. and Reboldi, G. ( 2007) Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens20: 154-161.
65.
Volpe, M., Brommer, P., Haag, U. and Miele, C.(2009a) Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig29: 11-25.
66.
Volpe, M., Miele, C. and Haag, U.(2009b) Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: An open-label, long-term study. Clin Drug Investig29: 381-391.
67.
Wang, Y.R., Alexander, G.C. and Stafford, R.S. ( 2007) Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med167: 141-147.
68.
Weir, M.R., Weber, M.A., Nesbitt, S.D., Hsueh, W.A., Neutel, J.M. and Jaffe, J. ( 2009) Rationale and design of the BP CRUSH study: Evaluating the efficacy and safety of amlodipine/olmesartan medoxomil in patients who are non-responders to antihypertensive mono- therapy. J Clin Hypertens11: A137.
